Bilal J, et al. - Herein, authors attempted to appraise the efficacy and safety of inhibitors of interleukin 6 (IL-6): Clazakizumab, IL-12/23: Ustekinumab, and IL-17A: Secukinumab, brodalumab, and ixekizumab in the management of psoriatic arthritis (PsA). Findings illustrated the efficacy of inhibitors of IL-6 (clazakizumab), IL-12/23 (ustekinumab), and IL-17A (secukinumab, brodalumab, ixekizumab) in patients who were tumor necrosis factor naive, as well as tumor necrosis factor nonresponders or inadequate responders. These drugs were disclosed to be generally well tolerated when used to treat patients with PsA.